^
Association details:
| Biomarker: | SNAI2 deletion |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | abiraterone acetate (CYP17A1 inhibitor) + Firmagon (degarelix) (GnRH antagonist) + Biolen (bicalutamide implant) (Androgen receptor antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Loss of SNAI2 in Prostate Cancer Correlates With Clinical Response to Androgen Deprivation Therapy
Published date:
06/02/2021
Excerpt:
We evaluated a novel combination of AR-targeting therapies (degarelix, abiraterone, and bicalutamide) and noted that the objective patient response to therapy was highly variable...treatment response correlating with the prevalence of tumor cells deficient for SNAI2...These findings indicate that SNAI2 has potential as a predictive biomarker of response to AR-targeting drugs...
DOI:
10.1200/PO.20.00337 JCO Precision Oncology
